Da Hee Han, PharmD

Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container.

The Food and Drug Administration (FDA) has issued a warning letter to CanaRx, a company operating as a prescription drug provider, for its involvement in the distribution of certain unapproved or misbranded drugs that may be harmful to US consumers. The letter includes the agency’s concerns with the “scheme CanaRx uses to contract with public…

The CAROLINA trial met its primary endpoint, demonstrating no increased CV risk with linagliptin, a DPP-4 inhibitor, when compared with glimepiride, a sulfonylurea, in patients with type 2 diabetes and CV risk.

Regeneron and Sanofi announced that both doses of Praluent will be made available at a new US list price—60% lower than the original—in early March.

Alyq should not be used with concomitant organic nitrates or guanylate cyclase (GC) stimulators (eg, riociguat), and in patients with a known serious hypersensitivity to tadalafil.

The FDA has issued a statement regarding the ongoing investigation into potentially carcinogenic impurities identified in some angiotensin II receptor blockers.

The FDA’s communication follows a recent meta-analysis published in the Journal of the American Heart Association.

Tafamidis is an oral small molecule candidate that selectively binds at specific sites on the transthyretin tetramer to prevent destabilization of the transthyretin transport protein and formation of amyloid that causes ATTR-CM.

HeartGuide is designed as a wrist watch that uses the oscillometric cuff method, the standard for medical-grade personal blood pressure measurement.

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an on-body infusor with prefilled cartridge.